A new study has identified three genetic changes in East Asian women linked to an increased risk of breast cancer.
For a rare form of cancer called thymoma, researchers have discovered a single gene defining the difference between a fast-growing tumor requiring aggressive treatment and a slow-growing tumor that does not require extensive therapy.
Researchers have discovered more than 40 genes that predict the level of aggressiveness of melanoma and that distinguish it from other cancers with a poor prognosis.
A new approach demonstrated that the recognition of unique cancer mutations appeared to be responsible for complete cancer regressions in two metastatic melanoma patients treated with a type of immunotherapy.
The protein galectin-1 has been identified as a possible therapeutic target for pancreatic cancer; new research has demonstrated that inhibiting this protein in mice with pancreatic cancer increased survival by 20%.
Circulating tumor cells captured with a microchip-based device can be cultured to establish cell lines for genetic analysis and drug testing.
Researchers from the University of Illinois at Chicago have discovered how cholesterol activates a cellular signaling pathway linked to cancer development. Previous studies have associated high cholesterol with certain cancers. But in this study, the researchers focused on the signaling pathways used to direct cell function.
Scientists have shown that a new drug could prove useful in treating small cell lung cancer, the most aggressive form of lung cancer.
Two genetic mutations in liver cells may drive tumor formation in intrahepatic cholangiocarcinoma (iCCA), the second most common form of liver cancer, according to new research.
The era of personalized medicine for breast cancer may be just around the corner, thanks to recent advances by USC Stem Cell researcher Min Yu and scientists at Massachusetts General Hospital and Harvard Medical School.
Key genetic variants may affect how cancer patients respond to radiation treatments, according to a new study.
New research shows the protein neurons use to stay alive and healthy is used by brain cancer cells to maintain longevity to grow and metastasize. The findings could lead to breakthroughs in treatments for brain cancer.
New genome-based technology for the diagnosis of rare genetic illnesses is moving rapidly from research laboratories into general medical practice.
This overview offers a simple guide for explaining to patients the difference between the terms, the tests, and what the results may mean.
Tumor sequencing of several different lung cancers and their surrounding tissue complicates the prevailing theory of linear lung cancer progression and offers new insights for management of this deadly cancer.
With accelerating development of personalized cancer treatments matched to a patient's DNA sequencing, proponents of these treatments say frontline physicians increasingly need help finding the best individualized therapy.
Scientists have identified the cancer-specific stem cell that causes gastric cancer. This discovery opens up the possibility of developing new drugs for the treatment of this disease and other types of cancers.
A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient's body and responses to treatment.
Patients with a variety of hematologic cancers benefited from treatment with OTX015, a member of a new class of investigational epigenetic therapies that block the activity of bromodomain and extraterminal (BET)-bromodomain proteins.
Combining Mutant-Allele Tumor Heterogeneity (MATH) as a biomarker with a patient's HPV status provides an effective indicator of improved patient outcome.
The most common genetic alteration ever reported in the brain tumor ependymoma has been identified. Researchers also have evidence that the alteration drives tumor development.
Researchers report that a normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia, to promote progression of the disease.
In research that could ultimately lead to many new medicines, scientists have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die.
Pancreatic stellate cells, which normally aid tissue repair, unwittingly help pancreatic cancer grow and spread in a method of cell hijack only seen before in brain and breast cancer, according to new research. The research also revealed that the process can be blocked, thereby preventing the growth and spread of the tumor.
The protein SPOP, which is most frequently mutated in human prostate cancers, is a key regulator of androgen receptor activity that prevents uncontrolled growth of cells in the prostate and thus helps prevent cancer.
A new study shows that targeting a particular nuclear protein may provide an effective approach for treating triple-negative breast cancer.
Possible genetic origins of breast cancer that spreads to the brain have been uncovered, according to a first-of-its-kind study.
Small noncoding RNAs can be used to predict if a person has breast cancer, concluded researchers who contributed to The Cancer Genome Atlas (TCGA) project.
Concerns related to direct-to-consumer genomic testing include lack of evidence for association studies being appropriate as screening tests.
By combining a zebrafish model of liver cancer with data from human tumors, researchers hope to identify potential genes of interest that can be targeted for new treatments for hepatocellular carcinoma.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|